

Reference:	FOI.15739.24
Subject:	Wet Age-related Macular Degeneration (AMD)
Date of Request:	17 October 2024

Requested:

- 1) In the last 12 months of data that you have available, how many patients were treated for wet AMD (wet age-related macular degeneration) (ICD-10 Code H35.30) with the following agents:
 - a) Bevacizumab
 - b) Faricimab
 - c) Ranibizumab
 - d) Aflibercept

- 2) If possible to answer, in the last 12 months of data that you have available, how many other ophthalmology patients have you treated with the following agents (please list how many for each agent separately):
 - a) Bevacizumab
 - b) Faricimab
 - c) Ranibizumab
 - d) Aflibercept

Response:

- 1) Hywel Dda University Health Board (UHB) provides within the table below, the number of patients treated for wet AMD with the listed medications, during the period 1 October 2023 to 30 September 2024.

Medication	Number
a) Bevacizumab	0
b) Faricimab	7
c) Ranibizumab	321
d) Aflibercept	167

- 2) The UHB provides within the table below, the number of other ophthalmology patients treated with the listed medications, during the period 1 October 2023 to 30 September 2024.

Medication	Number
a) Bevacizumab	0
b) Faricimab	5
c) Ranibizumab	226
d) Aflibercept	177

Please note: - each patient is only being counted once. Therefore, if a patient changed medication, it will not be reflected in the data provided.